Letrozol Ratiopharm

Letrozole, the active ingredient in Letrozol Ratiopharm, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can stimulate tumor growth.

GNH USA supplies Letrozol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole acts on the estrogen synthesis pathway and is used in the management of hormone‑dependent breast cancer. - Hormone receptor‑positive metastatic breast cancer in postmenopausal women: reduces estrogen production to inhibit tumor progression. - Early‑stage hormone receptor‑positive breast cancer (adjuvant setting) in postmenopausal women: lowers recurrence risk after surgery. - Extended adjuvant therapy after 5 years of tamoxifen in postmenopausal women: provides continued estrogen suppression to prevent disease return.

Letrozole may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Increased sweating

Serious or Rare Side Effects: - Osteoporosis or bone fractures - Severe liver injury - Pulmonary embolism or deep‑vein thrombosis - Anaphylactic or severe allergic reactions - Elevated cholesterol levels

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly. - Pregnancy contraindication: avoid use in pregnant women; Letrozole is classified as Category X. - Bone health monitoring: assess bone mineral density periodically. - Liver function: check hepatic enzymes before and during treatment. - Lipid profile: monitor cholesterol levels regularly. - Premenopausal status: do not use in premenopausal women unless ovarian suppression is confirmed. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract Letrozole’s effect. - Strong CYP2C19 inhibitors (e.g., ketoconazole): can increase Letrozole plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): may reduce Letrozole exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect. - Tamoxifen: concurrent use may affect hormonal balance. - Selective serotonin reuptake inhibitors (e.g., paroxetine): potential CYP2D6 interaction. - Statins: monitor lipid changes. - Glucocorticoids: observe for additive bone‑loss risk.